Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
December 16, 2024 4:14 AM ESTGoldman Sachs analyst Chris Shibutani reiterated a Buy rating and $33.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Ahead of PFE's 2025 Guidance call (Tuesday, December 17) we outline our expectations for the guide and commentary on the upcoming year. Overall, we anticipate that PFE management will guide to earnings (EPS) in the mid-to-high $2 range with core business growth offset by... More
